Business
Patent Granted in Japan
Patent Granted in Japan.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n RNS Number : 3844V Allergy Therapeutics PLC 09 July 2009 \n \n9 July 2009\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n\nKey Technology Patent for Pollinex® Quattro in Japan granted \n\nAllergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that it has been granted a broad technology patent for Pollinex® Quattro by the Japanese Patent Office. The patent covers the use of allergens in combination with tyrosine and monophosphoryl lipid A (MPL®).\n\nPollinex Quattro is a modern, adjuvanted vaccine and has a unique short dosing course of four injections. Approval of the patent follows the submission of the Pollinex Quattro Grass dossier for regulatory approval in the European Union on the 3rd of March and the announcement in 2008 of the successful completion of Phase III studies for both Pollinex Quattro Grass and Pollinex Quattro Ragweed. These two studies are the largest controlled allergy vaccine studies ever conducted. In both studies the primary efficacy endpoint was met and Pollinex Quattro demonstrated significant clinical benefits in efficacy, safety and patient compliance over placebo. \n\nAs part of the Company's strategy to meet growing demand for Pollinex Quattro, Allergy Therapeutics has been conducting pre-clinical work with Japanese Cedar which is the single most significant pollen in Japan. The Company will proceed with clinical trials when a suitable partner is found. Compelling evidence of the efficacy and of the safety profile of Pollinex Quattro means that the Company is in a strong position to attract potential partners in Japan.\n\nKeith Carter, Chief Executive of Allergy Therapeutics, said: \"29 million people suffer from allergic rhinitis in Japan. It is a large and growing market in which we have successfully secured patent protection for Pollinex Quattro allowing us, through partners, to exploit fully the opportunity this market presents.\"\n\n&...